Showing 641 - 660 results of 901 for search '"Alzheimers"', query time: 0.06s Refine Results
  1. 641

    Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases? by Stefania Gonfloni, Emiliano Maiani, Claudia Di Bartolomeo, Marc Diederich, Gianni Cesareni

    Published 2012-01-01
    “…In line with these observations, an increased c-Abl activation is reported in human neurodegenerative pathologies, such as Parkinson’s, and Alzheimer’s diseases. This suggests that aberrant nonspecific posttranslational modifications induced by c-Abl may contribute to fuel the recurrent phenotypes/features linked to neurodegenerative disorders, such as an impaired mitochondrial function, oxidative stress, and accumulation of protein aggregates. …”
    Get full text
    Article
  2. 642

    Movement in the Shadow of Sadness: How Physical Activity Supports the Fight Against Depression by Agata Ossolińska, Patrycja Marta, Filip Huzarski, Gabriela Ferfecka, Klaudia Pawełek, Lucyna Stolarska, Magdalena Rosa-Bończak, Natalia Morawiecka, Olivier Carlton, Weronika Kłosowicz

    Published 2025-02-01
    “…Research indicates that regular physical exercise, such as aerobic or strength training, aids in the prevention and treatment of mental disorders such as depression, schizophrenia, and Alzheimer’s disease. The biological mechanisms associated with physical activity include improved cerebral blood flow, modulation of neurotransmitter systems, and increased levels of neurotrophic factors like BDNF. …”
    Get full text
    Article
  3. 643

    Interaction of Herbal Compounds with Biological Targets: A Case Study with Berberine by Xiao-Wu Chen, Yuan Ming Di, Jian Zhang, Zhi-Wei Zhou, Chun Guang Li, Shu-Feng Zhou

    Published 2012-01-01
    “…In addition, berberine was found to interact with a mixture of biological pathways, such as Alzheimer’s disease-presenilin and -secretase pathways, angiogenesis, apoptosis signalling pathway, FAS signalling pathway, Hungtington disease, inflammation mediated by chemokine and cytokine signalling pathways, interleukin signalling pathway, and p53 pathways. …”
    Get full text
    Article
  4. 644

    The role of the corticotropin-releasing hormone and its receptors in the regulation of stress response by E. V. Sukhareva

    Published 2021-04-01
    “…Disturbances of the CRH system regulation are directly related to such disorders: mental pathologies (depression, anxiety, addictions), deviations of neuroendocrinological functions, inflammation, as well as the onset and development of neurodegenerative diseases such as Alzheimer’s disease. In addition, the role of CRH as a regulator of the neurons structure in the areas of the developing and mature brain has been established. …”
    Get full text
    Article
  5. 645

    Role of Inflammasomes in Neuroimmune and Neurodegenerative Diseases: A Systematic Review by Yue Lang, Fengna Chu, Donghui Shen, Weiguanliu Zhang, Chao Zheng, Jie Zhu, Li Cui

    Published 2018-01-01
    “…Many recent studies suggest a strong correlation between inflammasomes and neurological diseases, such as multiple sclerosis (MS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). …”
    Get full text
    Article
  6. 646

    NMR probing of copper–amyloid β1–16 interactions and self-assembly by Punnepalli Sunanda, Srinivasarao Raghothama, Uma Maheswari Devi Palempalli, Bankala Krishnarjuna

    Published 2024-12-01
    “… Trace metal ions, such as copper, play an important role in the development of amyloid β (Aβ)-mediated Alzheimer’s disease (AD). Atomic-level investigation of Aβ interaction with copper ions is essential for understanding the metal-mediated peptide self-assembly. …”
    Get full text
    Article
  7. 647

    Behavioral phenotyping of mice deficient for tumor necrosis factor by D. V. Fursenko, N. V. Khotskin, V. A. Kulikov, A. V. Kulikov

    Published 2015-12-01
    “…It has been demonstrated that TNF plays roles in such diseases as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. …”
    Get full text
    Article
  8. 648

    Impaired Hippocampal Glutamate and Glutamine Metabolism in the db/db Mouse Model of Type 2 Diabetes Mellitus by Jens Velde Andersen, Jakob Dahl Nissen, Sofie Kjellerup Christensen, Kia Hjulmand Markussen, Helle Sønderby Waagepetersen

    Published 2017-01-01
    “…Type 2 diabetes mellitus (T2DM) is a risk factor for the development of Alzheimer’s disease, and changes in brain energy metabolism have been suggested as a causative mechanism. …”
    Get full text
    Article
  9. 649

    Semantic Dementia Shows both Storage and Access Disorders of Semantic Memory by Yumi Takahashi, Kenichi Meguro, Masahiro Nakatsuka, Mari Kasai, Kyoko Akanuma, Satoshi Yamaguchi

    Published 2014-01-01
    “…The results were compared with those for 6 patients with Alzheimer’s disease (AD). Results. The SD patients had lower scores than the AD group for both tasks, suggesting both storage and access disorders. …”
    Get full text
    Article
  10. 650

    Predicting Cognitive Decline in Parkinson’s Disease with Mild Cognitive Impairment: A One-Year Observational Study by Pei-Hao Chen, Fang-Yu Cheng, Shih-Jung Cheng, Jin-Siang Shaw

    Published 2020-01-01
    “…We conducted an observational study to investigate clinical predictors of cognitive decline in patients with mild cognitive impairment (MCI), with a focus on patients with Parkinson’s disease (PD) and Alzheimer’s disease (AD). The study was performed with detailed neuropsychological testing, a portable device for gait analysis, and a comprehensive geriatric assessment for patients with MCI. …”
    Get full text
    Article
  11. 651

    Comorbidities among Patients with Epilepsy Attending Imam Al-Sadiq General Hospital in Babylon Governorate, Iraq by Bilal Hadi Jawad, Khadija Shaban Hassan, Wahab Razzaq Ebdan

    Published 2022-11-01
    “…Among psychiatric comorbidities, 67.1% of them were suffered from anxiety and 61.9% with depression. 7.6% of patient were suffering from Dementia/ Alzheimer’s disease as cognitive comorbidities. It found an increased risk for full spectrum of medical, psychiatric disorders. …”
    Get full text
    Article
  12. 652

    Multipotent Effect of Clozapine on Lipopolysaccharide-Induced Acetylcholinesterase, Cyclooxygenase-2,5-Lipoxygenase, and Caspase-3: In Vivo and Molecular Modeling Studies by Minhajul Arfeen, Devendra Kumar Dhaked, Vasudevan Mani

    Published 2025-01-01
    “…Dual inhibition of cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) is a recognized strategy for enhanced anti-inflammatory effects in small molecules, offering potential therapeutic benefits for individuals at risk of dementia, particularly those with neurodegenerative diseases, common cancers, and diabetes type. Alzheimer’s disease (AD) is the most common cause of dementia, and the inhibition of acetylcholinesterase (AChE) is a key approach in treating AD. …”
    Get full text
    Article
  13. 653

    The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets across neurodegenerative conditions by Ricardo Martins-Ferreira, Josep Calafell-Segura, Bárbara Leal, Javier Rodríguez-Ubreva, Elena Martínez-Saez, Elisabetta Mereu, Paulo Pinho E Costa, Ariadna Laguna, Esteban Ballestar

    Published 2025-01-01
    “…We constructed an atlas of human brain immune cells by integrating nineteen single-nucleus RNA-seq and single-cell RNA-seq datasets from multiple neurodegenerative conditions, comprising 241 samples from patients with Alzheimer’s disease, autism spectrum disorder, epilepsy, multiple sclerosis, Lewy body diseases, COVID-19, and healthy controls. …”
    Get full text
    Article
  14. 654

    The Diagnostic Role of Serum Inflammatory and Soluble Proteins on Dementia Subtypes: Correlation with Cognitive and Functional Decline by Candan Öztürk, Aynur Özge, Osman Özgür Yalın, İ. Arda Yılmaz, Nuran Delialioglu, Çilem Yıldız, Bahar Tesdelen, Cigdem Kudiaki

    Published 2007-01-01
    “…However there are restricted data about the profile of the inflammatory and soluble proteins in well evaluated Alzheimer’s disease (AD), vascular dementia (VD), mild cognitive impairment (MCI) and healthy controls. …”
    Get full text
    Article
  15. 655

    A Novel Metabolic Connectome Method to Predict Progression to Mild Cognitive Impairment by Min Wang, Zhuangzhi Yan, Shu-yun Xiao, Chuantao Zuo, Jiehui Jiang

    Published 2020-01-01
    “…Glucose-based positron emission tomography (PET) imaging has been widely used to predict the progression of mild cognitive impairment (MCI) into Alzheimer’s disease (AD) clinically. However, existing discriminant methods are unsubtle to reveal pathophysiological changes. …”
    Get full text
    Article
  16. 656

    A realistic human head phantom for electromagnetic detection of brain diseases by Zelin Bai, Diyou Chen, Ke Ma, Gui Jin, Jinlong Qiu, Quanquan Li, Haocheng Li, Mingsheng Chen

    Published 2025-01-01
    “…It proved valuable for studying the distribution of electromagnetic fields in the human head and for investigating novel electromagnetic detection techniques exploiting brain tissue dielectric properties. (4) The created physical model and the numerical model were derived from the same person, which provided a good continuity between simulation experiments and physical experiments, and provided a realistic verification platform for the research of electromagnetic detection technology for brain diseases, such as differentiating the kind of stroke, monitoring brain edema, brain tumor microwave imaging, and diagnosis of Alzheimer’s disease.…”
    Get full text
    Article
  17. 657

    PPARγ and the Innate Immune System Mediate the Resolution of Inflammation by Amanda Croasdell, Parker F. Duffney, Nina Kim, Shannon H. Lacy, Patricia J. Sime, Richard P. Phipps

    Published 2015-01-01
    “…These effects contribute towards the attenuation of multiple disease states, including COPD, colitis, Alzheimer’s disease, and obesity in animal models. Finally, novel specialized proresolving mediators—eicosanoids with critical roles in resolution—may act through PPARγ modulation to promote resolution, providing another exciting area of therapeutic potential for this receptor.…”
    Get full text
    Article
  18. 658

    The Tree-Drawing Test (Koch’s Baum Test): A Useful Aid to Diagnose Cognitive Impairment by Michelangelo Stanzani Maserati, Corrado Matacena, Luisa Sambati, Federico Oppi, Roberto Poda, Maddalena De Matteis, Roberto Gallassi

    Published 2015-01-01
    “…Consecutive outpatients were classified as affected by dementia (Alzheimer’s disease (AD), frontotemporal dementia (FTD), and vascular dementia (VD)) or by MCI. …”
    Get full text
    Article
  19. 659

    Detection of Amylin-β-amyloid Hetero-Oligomers by Enzyme-Linked Immunosorbent Assay by Noah Leibold, Deepak Kotiya, Nirmal Verma, Florin Despa

    Published 2025-02-01
    “…Parenchymal amylin-Aβ plaques are found in both sporadic and early-onset familial Alzheimer’s disease (AD), yet their (patho)physiological role remains elusive, particularly due to a lack of detection modalities for these mixed plaques. …”
    Get full text
    Article
  20. 660

    Coccoloba uvifera (L.) (Polygonaceae) Fruit: Phytochemical Screening and Potential Antioxidant Activity by Maira Rubi Segura Campos, Jorge Ruiz Ruiz, Luis Chel-Guerrero, David Betancur Ancona

    Published 2015-01-01
    “…Antioxidant compounds are now of considerable interest due to their effect of preventing or delaying aging and their apparent involvement in prevention of numerous human diseases, including cancer, atherosclerosis, Alzheimer’s disease, inflammation, and rheumatoid arthritis. …”
    Get full text
    Article